Literature DB >> 31558653

Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R.

Leonhard A Bakker1,2, Carin D Schröder2,3, Harold H G Tan1, Simone M A G Vugts1, Ruben P A van Eijk1,4, Michael A van Es1, Johanna M A Visser-Meily2,3, Leonard H van den Berg5.   

Abstract

OBJECTIVE: The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) is widely applied to assess disease severity and progression in patients with motor neuron disease (MND). The objective of the study is to assess the inter-rater and intra-rater reproducibility, i.e., the inter-rater and intra-rater reliability and agreement, of a self-administration version of the ALSFRS-R for use in apps, online platforms, clinical care and trials.
METHODS: The self-administration version of the ALSFRS-R was developed based on both patient and expert feedback. To assess the inter-rater reproducibility, 59 patients with MND filled out the ALSFRS-R online and were subsequently assessed on the ALSFRS-R by three raters. To assess the intra-rater reproducibility, patients were invited on two occasions to complete the ALSFRS-R online. Reliability was assessed with intraclass correlation coefficients, agreement was assessed with Bland-Altman plots and paired samples t-tests, and internal consistency was examined with Cronbach's coefficient alpha.
RESULTS: The self-administration version of the ALSFRS-R demonstrated excellent inter-rater and intra-rater reliability. The assessment of inter-rater agreement demonstrated small systematic differences between patients and raters and acceptable limits of agreement. The assessment of intra-rater agreement demonstrated no systematic changes between time points; limits of agreement were 4.3 points for the total score and ranged from 1.6 to 2.4 points for the domain scores. Coefficient alpha values were acceptable. DISCUSSION: The self-administration version of the ALSFRS-R demonstrates high reproducibility and can be used in apps and online portals for both individual comparisons, facilitating the management of clinical care and group comparisons in clinical trials. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  agreement; amyotrophic lateral sclerosis; amyotrophic lateral sclerosis functional rating scale-revised; inter-rater; intra-rater; reliability; reproducibility

Mesh:

Year:  2019        PMID: 31558653     DOI: 10.1136/jnnp-2019-321138

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  4 in total

1.  Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF).

Authors:  Ruben P A van Eijk; L H van den Berg; Ying Lu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-12-17       Impact factor: 13.654

Review 2.  Telemedicine for management of patients with amyotrophic lateral sclerosis through COVID-19 tail.

Authors:  Alessandro Bombaci; Gianmarco Abbadessa; Francesca Trojsi; Letizia Leocani; Simona Bonavita; Luigi Lavorgna
Journal:  Neurol Sci       Date:  2020-10-06       Impact factor: 3.307

Review 3.  Qualitative measures that assess functional disability and quality of life in ALS.

Authors:  Susan L Hartmaier; Thomas Rhodes; Suzanne F Cook; Courtney Schlusser; Chao Chen; Steve Han; Neta Zach; Venkatesha Murthy; Shreya Davé
Journal:  Health Qual Life Outcomes       Date:  2022-01-21       Impact factor: 3.186

4.  Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the D50 disease progression model.

Authors:  Robert Steinbach; Nayana Gaur; Annekathrin Roediger; Thomas E Mayer; Otto W Witte; Tino Prell; Julian Grosskreutz
Journal:  Hum Brain Mapp       Date:  2020-10-26       Impact factor: 5.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.